Comparative Pharmacology
Head-to-head clinical analysis: CORTENEMA versus HYDROCORTISONE ACETATE 1 AND PRAMOXINE HYDROCHLORIDE 1.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CORTENEMA versus HYDROCORTISONE ACETATE 1 AND PRAMOXINE HYDROCHLORIDE 1.
CORTENEMA vs HYDROCORTISONE ACETATE 1% AND PRAMOXINE HYDROCHLORIDE 1%
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Corticosteroid that binds to the glucocorticoid receptor, modulating gene expression to inhibit phospholipase A2, reduce prostaglandin and leukotriene synthesis, decrease cytokine production, and suppress inflammatory cell migration and activation in the colonic mucosa.
Hydrocortisone acetate is a corticosteroid that binds to glucocorticoid receptors, modulating gene expression to reduce inflammation, vasodilation, and immune cell activity. Pramoxine hydrochloride is a local anesthetic that reversibly blocks sodium ion channels in nerve cell membranes, inhibiting nerve impulse conduction and providing topical anesthesia.
One enema (100 mg hydrocortisone in 60 mL) administered rectally once daily, preferably at bedtime, for 21 days or until clinical response.
Apply a thin film to affected area three to four times daily. Topical only.
None Documented
None Documented
1.8-3.5 hours (plasma); due to rectal administration and low systemic absorption, clinical effects persist longer than plasma levels suggest
Hydrocortisone acetate: 1.5–2 hours (plasma), clinically adrenocortical suppression lasts 24–48 hours; pramoxine: not applicable due to minimal absorption.
Primarily hepatic metabolism with renal excretion of inactive metabolites; <5% unchanged in urine; biliary/fecal elimination of metabolites accounts for ~80%
Hydrocortisone acetate: primarily renal (about 90% as metabolites, less than 1% unchanged); pramoxine HCl: negligible systemic absorption, eliminated primarily via fecal excretion.
Category C
Category D/X
Corticosteroid
Corticosteroid